Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The collaboration will center on expanding access to Eastman’s Esmeri technology
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The new functionality complements Parse’s existing Evercode immune products
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated